GLP-1 Market
LLY $1149.85 ▼ -0.6% NVO $37.40 ▼ -1.3% PFE $28.12 ▼ -1.4% VKTX $30.51 ▼ -6.4% KLRA $11.03 ▼ -3.4% GPCR $28.98 ▼ -7.3% RHHBY $52.35 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

RO7795081

RO7795081

Company
Hoffmann-La Roche
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 2, 2026

Find a Clinical Trial Near Me

See recruiting studies for RO7795081 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07741604

    A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions

    Not yet reported Hoffmann-La Roche 60 participants Est. completion 2028-02-01 2 sites Stand-alone
    Other conditions: Renal Impairment
    View official trial listing →
  • Completed NCT NCT05814107

    Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

    Not yet reported Carmot Australia First Pty Ltd 94 participants Est. completion 2025-11-07 2 sites Stand-alone
    Type 2 diabetes Other conditions: Overweight or Obesity
    View official trial listing →
  • Completed NCT NCT06809608

    A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081

    Not yet reported Hoffmann-La Roche 36 participants Est. completion 2025-05-28 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Active, not recruiting NCT NCT06982131

    A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

    Not yet reported Hoffmann-La Roche 40 participants Est. completion 2026-12-07 1 site Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT07081958

    A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

    Not yet reported Hoffmann-La Roche 352 participants Est. completion 2026-07-30 36 sites Stand-alone
    Other conditions: Obesity or Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07112872

    A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

    Not yet reported Hoffmann-La Roche 330 participants Est. completion 2028-02-05 46 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07499050

    A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

    Not yet reported Hoffmann-La Roche 30 participants Est. completion 2027-01-09 2 sites Stand-alone
    Other conditions: Healthy Volunteers, Overweight or Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: RO7795081, CT-996, RG6652

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.